晚期结直肠癌的化疗进展

被引：40

作者：

李文桦

张文

机构：

[1] 复旦大学附属肿瘤医院肿瘤内科复旦大学上海医学院肿瘤学系

来源：

中国癌症杂志 | 2015年 / 25卷 / 11期

关键词：

结直肠癌; 化疗; 转移;

D O I：

暂无

中图分类号：

R735.34 [];

学科分类号：

摘要：

化疗是晚期结直肠癌的主要治疗手段,以氟尿嘧啶(5-fluorouracil,5-FU)、奥沙利铂和伊立替康为主的三药是晚期肠癌治疗的重要药物,联合化疗和"打打停停"的治疗模式在提高疗效的同时兼顾了治疗的耐受性。新的化疗药物雷替曲塞、替吉奥和TAS-102也在临床中获得应用。就晚期结直肠癌化疗的进展进行综述。

引用

页码：877 / 889

页数：13

共 16 条

[1]

中国人尿苷二磷酸葡糖苷酸转移酶1A基因多态性与伊立替康毒性的相关性.[J].王岩;徐建明;沈琳;徐农;王金万;焦顺昌;张京生;宋三泰;李健;包悍英;杨林;李方;.中华肿瘤杂志.2007, 12

[2]

The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer [J].

Nakamura, Masato ;

Yamada, Yasuhide ;

Muro, Kei ;

Takahashi, Keiichi ;

Baba, Hideo ;

Sasaki, Yasutsuna ;

Komatsu, Yoshito ;

Satoh, Taroh ;

Mishima, Hideyuki ;

Watanabe, Masahiko ;

Sakata, Yuh ;

Morita, Satoshi ;

Shimada, Yasuhiro ;

Sugihara, Kenichi .

FUTURE ONCOLOGY, 2015, 11 (10) :1471-1478

[3]

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians [J].

Cheng, Lei ;

Li, Ming ;

Hu, Jing ;

Ren, Wei ;

Xie, Li ;

Sun, Zhan-Peng ;

Liu, Bao-Rui ;

Xu, Gen-Xing ;

Dong, Xiao-Liang ;

Qian, Xiao-Ping .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) :551-560

[4]

Capecitabine Plus Irinotecan Versus 5-FU/Leucovorin Plus Irinotecan in the Treatment of Colorectal Cancer: A Meta-analysis [J].

Guo, Yuanbiao ;

Shi, Min ;

Shen, Xiaoheng ;

Yang, Chen ;

Yang, Liu ;

Zhang, Jun .

CLINICAL COLORECTAL CANCER, 2014, 13 (02) :110-118

[5]

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial [J].

Yoshino, Takayuki ;

Mizunuma, Nobuyuki ;

Yamazaki, Kentaro ;

Nishina, Tomohiro ;

Komatsu, Yoshito ;

Baba, Hideo ;

Tsuji, Akihito ;

Yamaguchi, Kensei ;

Muro, Kei ;

Sugimoto, Naotoshi ;

Tsuji, Yasushi ;

Moriwaki, Toshikazu ;

Esaki, Taito ;

Hamada, Chikuma ;

Tanase, Takanori ;

Ohtsu, Atsushi .

LANCET ONCOLOGY, 2012, 13 (10) :993-1001

[6]

Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil; leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).[J]..European Journal of Cancer.2012,

[7]

Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer [J].

Komatsu, Yoshito ;

Yuki, Satoshi ;

Sogabe, Susumu ;

Fukushima, Hiraku ;

Nakatsumi, Hiroshi ;

Kobayashi, Yoshimitsu ;

Iwanaga, Ichiro ;

Nakamura, Michio ;

Hatanaka, Kazuteru ;

Miyagishima, Takuto ;

Kudo, Mineo ;

Munakata, Masaki ;

Meguro, Takashi ;

Tateyama, Miki ;

Sakata, Yuh .

ACTA ONCOLOGICA, 2012, 51 (07) :867-872

[8]

Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label; randomised; phase 3 trial.[J].Michel Ducreux;David Malka;Jean Mendiboure;Pierre-Luc Etienne;Patrick Texereau;Dominique Auby;Philippe Rougier;Mohamed Gasmi;Marine Castaing;Moncef Abbas;Pierre Michel;Dany Gargot;Ahmed Azzedine;Catherine Lombard-Bohas;Patrick Geoffroy;Bernard Denis;Jean-Pierre Pignon;Laurent Bedenne;Olivier Bouché.Lancet Oncology.2011, 11

[9]

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer.[J].MichelDucreux;JaafarBennouna;MohamedHebbar;MarcYchou;GérardLledo;ThierryConroy;AntoineAdenis;RogerFaroux;ChristineRebischung;LoicBergougnoux;LeilaKockler;Jean‐YvesDouillard.Int. J. Cancer.2010, 3

[10]

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study) [J].

Muro, Kei ;

Boku, Narikazu ;

Shimada, Yasuhiro ;

Tsuji, Akihito ;

Sameshima, Shinichi ;

Baba, Hideo ;

Satoh, Taroh ;

Denda, Tadamichi ;

Ina, Kenji ;

Nishina, Tomohiro ;

Yamaguchi, Kensei ;

Takiuchi, Hiroya ;

Esaki, Taito ;

Tokunaga, Shinya ;

Kuwano, Hiroyuki ;

Komatsu, Yoshito ;

Watanabe, Masahiko ;

Hyodo, Ichinosuke ;

Morita, Satoshi ;

Sugihara, Kenichi .

LANCET ONCOLOGY, 2010, 11 (09) :853-860

← 1 2 →